Eli Lilly and Company (NYSE:LLY) Position Boosted by Paragon Private Wealth Management LLC

Paragon Private Wealth Management LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.2% during the 4th quarter, HoldingsChannel reports. The fund owned 1,323 shares of the company’s stock after purchasing an additional 89 shares during the period. Paragon Private Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,021,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. Principal Financial Group Inc. grew its stake in Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Eli Lilly and Company by 7.3% during the 3rd quarter. Assetmark Inc. now owns 49,713 shares of the company’s stock valued at $44,043,000 after buying an additional 3,397 shares during the last quarter. Field & Main Bank lifted its holdings in shares of Eli Lilly and Company by 0.3% during the 3rd quarter. Field & Main Bank now owns 8,172 shares of the company’s stock valued at $7,240,000 after buying an additional 27 shares during the last quarter. First Personal Financial Services lifted its holdings in shares of Eli Lilly and Company by 24.9% during the 3rd quarter. First Personal Financial Services now owns 301 shares of the company’s stock valued at $267,000 after buying an additional 60 shares during the last quarter. Finally, Sheets Smith Wealth Management lifted its holdings in shares of Eli Lilly and Company by 48.6% during the 3rd quarter. Sheets Smith Wealth Management now owns 13,065 shares of the company’s stock valued at $11,574,000 after buying an additional 4,271 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on LLY shares. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Truist Financial lifted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a report on Thursday, January 16th. Finally, Citigroup reduced their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,007.50.

Eli Lilly and Company Stock Performance

LLY opened at $868.59 on Monday. The stock has a market cap of $823.57 billion, a PE ratio of 74.17, a P/E/G ratio of 1.40 and a beta of 0.34. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The stock’s 50 day simple moving average is $826.63 and its 200-day simple moving average is $847.24.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.